首页> 外文期刊>中国癌症研究(英文版) >JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis
【24h】

JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis

机译:中国原发性骨髓纤维化患者的JAK2 V617F,MPL W515L和JAK2外显子12突变

获取原文
获取原文并翻译 | 示例
       

摘要

Objective:JAK2 V617F,MPL W515L and JAK2 exon 12 mutations are novel acquired mutations that induce constitutive cytokine-independent activation of the JAK-STAT pathway in myeloproliferative disorders (MPD).The discovery of these mutations provides novel mechanism for activation of signal transduction in hematopoietic malignancies.This research was to investigate their prevalence in Chinese patients with primary myelofibrosis (PMF).Methods:We introduced allele-specific PCR (AS-PCR) combined with sequence analysis to simultaneously screen JAK2 V617F,MPL W515L and JAK2 exon 12 mutations in 30 patients with PMF.Results:Fifteen PMF patients (50.0%) carried JAK2 V617F mutation,and only two JAK2 V617F-negative patients (6.7%) harbored MPL W515L mutation.None had JAK2 exon 12 mutations.Furthermore,these three mutations were not detected in 50 healthy controls.Conclusion:MPL W515L and JAK2 V617F mutations existed in PMF patients but JAK2 exon 12 mutations not.JAK2 V617F and MPL W515L and mutations might contribute to the primary molecular pathogenesis in patients with PMF.
机译:目的:JAK2 V617F,MPL W515L和JAK2外显子12突变是导致骨髓增生性疾病(MPD)中JAK-STAT途径的非依赖于细胞因子的本构激活的新型获得性突变。这些突变的发现为激活信号转导激活了新的机制。方法:我们引入等位基因特异性PCR(AS-PCR)结合序列分析,同时筛选JAK2 V617F,MPL W515L和JAK2外显子12突变,以研究其在中国原发性骨髓纤维化(PMF)患者中的患病率。结果:30例PMF患者中有15例(50.0%)携带JAK2 V617F突变,只有2例JAK2 V617F阴性患者(6.7%)携带MPL W515L突变。无JAK2外显子12突变。此外,这三个突变为结论:在PMF患者中存在MPL W515L和JAK2 V617F突变,但在JAK2外显子12突变中未检测到。JAK2V617F和MPL W515L及其他可能与PMF患者的主要分子发病机制有关。

著录项

  • 来源
    《中国癌症研究(英文版)》 |2012年第1期|72-76|共5页
  • 作者单位

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

    Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi 214023, China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号